ArticleJournal of diabetes and metabolic disorders2014
The cost of diabetes chronic complications among Iranian people with type 2 diabetes mellitus.
Article in Journal of diabetes and metabolic disorders, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study.BMC endocrine disorders · 2016Trial
- Prevalence of macro-vascular complications among type 2 diabetic adults aged 50 and over: results from Ardakan cohort study on aging (ACSA).Journal of diabetes and metabolic disorders · 2025Article
- Cost-of-Illness Analysis of Diabetic Foot Ulcer: A Prevalence-Based Approach in Southwest of Iran.Medical journal of the Islamic Republic of Iran · 2025Article
- The effect of telenursing follow-up on blood glycosylated hemoglobin and quality of life in the elderly with diabetes type 2.Journal of education and health promotion · 2025Article
- Altered expression of miR-375 and miR-541 in type 2 diabetes patients with and without coronary artery disease (CAD): the potential of miR-375 as a CAD biomarker.Journal of diabetes and metabolic disorders · 2024Article
- Cost-effectiveness and cost-utility analysis of type-2 diabetes screening in pharmacies in Iran.Research in pharmaceutical sciences · 2023Article
- Economic burden of type 2 diabetes in Iran: A cost-of-illness study.Health science reports · 2023Article
- Type 2 diabetes: patient assessment of chronic illness care.Journal of diabetes and metabolic disorders · 2021Article
- Diabetes in Iran: Prospective Analysis from First Nationwide Diabetes Report of National Program for Prevention and Control of Diabetes (NPPCD-2016).Scientific reports · 2017Article
- Evaluation the effect of 50 and 100 mg doses ofJournal of traditional and complementary medicine · 2017Article
- Correlation of Michigan neuropathy screening instrument, United Kingdom screening test and electrodiagnosis for early detection of diabetic peripheral neuropathy.Journal of diabetes and metabolic disorders · 2015Article
- The effect of self-care education program on reducing HbA1c levels in patients with type 2 diabetes.Journal of education and health promotion · 2014Article
- Iranian patients require more pertinent care to prevent type 2 diabetes complications.Advances in preventive medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the cost of diabetes related micro- and macrovascular complications in Iranian people with type 2 diabetes mellitus.
methodsIn routine clinical practice, people with type 2 diabetes mellitus were assessed for 10 years at a diabetes care center. The type of medications and clinical data were extracted from patients' documents. Mortality rate and the incidence of micro- and macrovascular complications recorded in patients' documents were analyzed. Cost analysis was comprised of 1) para clinic costs as well as laboratory, medications, clinical visits and nonmedical costs 2) inpatient costs as well as hospital admission costs, disability, and mortality costs.
resultsFrom 1562 people with type 2 diabetes mellitus, a total of 1000 patients with mean duration disease of 11.2 years, who had completed information in their documents, were studied. All people were free from complications at baseline. Mean cumulative incidence of diabetes-related complications over 10 years were 10.9 ± 3.5%, 8.0 ± 3.1%, 4.6 ± 1.7%, 9.1 ± 3.6% and 2.3 ± 0.9% for peripheral neuropathy and diabetic foot ulcer, nephropathy, ophthalmic complications, cardiovascular disease and death, respectively. People with better glycemic control had less complication and also related expenditures. Average para clinic cost per patient was 393.6 ± 47.8 and average inpatient cost per patient was 1520.7 ± 104.5 USD.
conclusionsOur findings demonstrate considerable incidence of diabetes chronic complications and also high health care expenditure for related complications among our patients. As the number of people with diabetes continues to rise, early detection of the disease and implementation of timely and appropriate therapeutic strategies could decrease the burden of diabetes chronic complications and also huge related expenditures.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.